Individuals can participate in the trial if they accept and meet the SPARKLE clinical study requirements*. Some of the key inclusion criteria are:
- Be male or female 18 years and older
- Have known focal liver lesions, or a physician might have expressed specific suspicion for that
- Have laboratory-confirmed severe renal impairment or acute kidney injury
- Be clinically stable (eg no underlying medical condition that, in the opinion of the investigator would be detrimental to the participant)
- Have no laboratory-confirmed moderate or severe hepatic impairment
Participants will be asked to take the investigational drug in the form of a mixed oral solution swallowed by mouth at one occasion. The entire study can be completed in 7 days, including two MRIs and a requested follow-up period. During the 3 or 4 follow-up visits participants’ safety condition and blood samples will be assessed and collected.  No investigational drug will be given during this period.
Successfully screened participants may be able to receive reimbursement for expenses and travel.
* More eligibility criteria can be found by clicking here
If you or someone you know may seem as a suitable candidate to participate in the SPARKLE clinical study please contact the study location nearest you.